Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD22 | P20273 | 9/20 | 0.58 |
| ▸ | MAG | P20916 | 4/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27391118 | 1.00 | CD22 (0.58) | CD22MAG | |
| SCHEMBL31225822 | 0.78 | CD22 (0.48) | CD22MAG | |
| SCHEMBL27390960 | 0.73 | CD22 (0.78) | CD22MAG | |
| SCHEMBL29325882 | 0.73 | CD22 (0.78) | CD22MAG | |
| SCHEMBL24630229 | 0.71 | CD22 (0.81) | CD22MAG | |
| SCHEMBL31225491 | 0.71 | CD22 (0.59) | CD22MAG | |
| SCHEMBL31225535 | 0.69 | CD22 (0.76) | CD22MAG | |
| SCHEMBL31226108 | 0.69 | CD22 (0.79) | CD22MAG | |
| SCHEMBL31225981 | 0.68 | CD22 (0.76) | CD22MAG | |
| SCHEMBL31502417 | 0.68 | CD22 (0.83) | CD22MAG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | ADAXION THERAPEUTICS, INC. | 2024-07-18 | — | — | US | disclosed |
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | ADAXION THERAPEUTICS, INC. | 2024-07-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216490-A1 | Autoantigens Engineered to Suppress Autoimmune Response | CD74, MICA, HLA-DRB1 | CD22 137/4885MAG 37/4885 |
| US-20240238422-A1 | Hypoimmunogenic Biotherapeutics | FCGR3B, CD47, IL2 | CD22 18/4885MAG 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.